Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment523% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-INT-3Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A
Supporting Documentation
- Data Definition Specification Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0608 : Understanding treatment effects and symptom dynamics in schizophrenia using network analysis
- 2024-0280 : Individual-level and study-level predictors of placebo response and dropout in Schizophrenia Disorder clinical trials
- 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2022-5062 : Heterogeneous treatment effects estimation with multi-source data: evidence from bipolar disorder and schizophrenia trials
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2021-4575 : A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
- 2021-4568 : Motor side effects and antipsychotic efficacy of antipsychotic drugs: An individual participant meta-analysis
- 2020-4521 : Causally interpretable meta-analysis with missing data: Generalizing evidence from bipolar disorder and schizophrenia trials to a target population
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2017-1676 : Placebo Effects in Schizophrenia
- 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
- 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis
- 2016-0766 : Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials
- 2015-0644 : Generalizing treatment effects for bipolar disorder and schizophrenia to the US population: Generalizability of network meta-analysis
- 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques
- 2014-0364 : Initial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual patient level analyses of placebo-controlled trials